{"id":"https://openalex.org/W3000739799","doi":"https://doi.org/10.2217/fon-2019-0762","title":"CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma","display_name":"CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma","publication_year":2020,"publication_date":"2020-01-17","ids":{"openalex":"https://openalex.org/W3000739799","doi":"https://doi.org/10.2217/fon-2019-0762","mag":"3000739799","pmid":"https://pubmed.ncbi.nlm.nih.gov/31951149"},"language":"en","primary_location":{"id":"doi:10.2217/fon-2019-0762","doi":"https://doi.org/10.2217/fon-2019-0762","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon-2019-0762","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.2217/fon-2019-0762","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007005578","display_name":"Michael Robert Migden","orcid":"https://orcid.org/0000-0003-3293-1208","observed_orcids":["https://orcid.org/0000-0003-3293-1208"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael R Migden","raw_affiliation_strings":["Departments of Dermatology & Head & Neck Surgery,University of Texas, MD Anderson Cancer Center, Houston, TX77030, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Dermatology & Head & Neck Surgery,University of Texas, MD Anderson Cancer Center, Houston, TX77030, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035539932","display_name":"Sunandana Chandra","orcid":"https://orcid.org/0000-0001-7936-5069","observed_orcids":["https://orcid.org/0000-0001-7936-5069"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sunandana Chandra","raw_affiliation_strings":["Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL60611, USA","Fax: +1 312 694 2740"],"raw_orcid":"https://orcid.org/0000-0001-7936-5069","affiliations":[{"raw_affiliation_string":"Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL60611, USA","institution_ids":["https://openalex.org/I111979921"]},{"raw_affiliation_string":"Fax: +1 312 694 2740","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057906544","display_name":"Guilherme Rabinowits","orcid":"https://orcid.org/0000-0001-5783-491X","observed_orcids":["https://orcid.org/0000-0001-5783-491X"]},"institutions":[{"id":"https://openalex.org/I1292848113","display_name":"Baptist Hospital of Miami","ror":"https://ror.org/000pfrh90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1292848113","https://openalex.org/I4210097785"]},{"id":"https://openalex.org/I4210097785","display_name":"Baptist Health South Florida","ror":"https://ror.org/00v47pv90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210097785"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guilherme Rabinowits","raw_affiliation_strings":["Hematology/Oncology, Miami Cancer Institute/Baptist Health South Florida, Miami, FL33176, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, Miami Cancer Institute/Baptist Health South Florida, Miami, FL33176, USA","institution_ids":["https://openalex.org/I1292848113","https://openalex.org/I4210097785"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016395117","display_name":"Chieh-I Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chieh-I Chen","raw_affiliation_strings":["Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103818406","display_name":"Jigar Desai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jigar Desai","raw_affiliation_strings":["Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050135291","display_name":"Alex Seluzhytsky","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex Seluzhytsky","raw_affiliation_strings":["Sanofi, Cambridge, MA02142, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Cambridge, MA02142, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064500437","display_name":"Medha Sasan\u00e9","orcid":"https://orcid.org/0000-0002-8288-3606","observed_orcids":["https://orcid.org/0000-0002-8288-3606"]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Medha Sasane","raw_affiliation_strings":["Sanofi, Bridgewater, NJ08807, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi, Bridgewater, NJ08807, USA","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011648369","display_name":"Benedetta Campanelli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benedetta Campanelli","raw_affiliation_strings":["Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100457690","display_name":"Zhen Chen","orcid":"https://orcid.org/0000-0002-4502-0801","observed_orcids":["https://orcid.org/0000-0002-4502-0801","https://orcid.org/0009-0000-8836-2724"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhen Chen","raw_affiliation_strings":["Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063848401","display_name":"Morganna Louise Freeman","orcid":"https://orcid.org/0000-0003-0314-7270","observed_orcids":["https://orcid.org/0000-0003-0314-7270"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Morganna L Freeman","raw_affiliation_strings":["Formerly of Department of Medical Oncology & Therapeutics Research,City of Hope Comprehensive Cancer Center, Duarte, CA91010, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Formerly of Department of Medical Oncology & Therapeutics Research,City of Hope Comprehensive Cancer Center, Duarte, CA91010, USA","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110797989","display_name":"Sherrif F. Ibrahim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sherrif F Ibrahim","raw_affiliation_strings":["Division of Dermatologic Surgery, University of Rochester Medical Center, Rochester, NY14642, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Dermatologic Surgery, University of Rochester Medical Center, Rochester, NY14642, USA","institution_ids":["https://openalex.org/I28792581"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058902095","display_name":"Nikhil I. Khushalani","orcid":"https://orcid.org/0000-0002-3636-4143","observed_orcids":["https://orcid.org/0000-0002-3636-4143"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nikhil I Khushalani","raw_affiliation_strings":["Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049431440","display_name":"Michael L. Andria","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Andria","raw_affiliation_strings":["Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals Inc., Tarrytown, NY10591, USA","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043968037","display_name":"Emily Stamell Ruiz","orcid":"https://orcid.org/0000-0001-5824-2721","observed_orcids":["https://orcid.org/0000-0001-5824-2721"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emily Ruiz","raw_affiliation_strings":["Department of Dermatology,Brigham & Women\u2019s Hospital, Harvard Medical School, Boston, MA02115, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology,Brigham & Women\u2019s Hospital, Harvard Medical School, Boston, MA02115, USA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":5.3124,"has_fulltext":false,"cited_by_count":39,"citation_normalized_percentile":{"value":0.96605652,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"16","issue":"4","first_page":"11","last_page":"19"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10307","display_name":"Head and Neck Cancer Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2733","display_name":"Otorhinolaryngology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cemiplimab","display_name":"cemiplimab","score":0.9610000252723694},{"id":"https://openalex.org/keywords/cutaneous-squamous-cell-carcinoma","display_name":"cutaneous squamous cell carcinoma","score":0.9279999732971191},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.5809999704360962},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.7429999709129333},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.6620000004768372},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.9539999961853027},{"id":"https://openalex.org/keywords/epidemiology","display_name":"epidemiology","score":0.6060000061988831},{"id":"https://openalex.org/keywords/metastatic-skin-cancer","display_name":"metastatic skin cancer","score":0.6570000052452087},{"id":"https://openalex.org/keywords/locally-advanced-skin-cancer","display_name":"locally advanced skin cancer","score":0.8199999928474426}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8017652034759521},{"id":"https://openalex.org/C172400760","wikidata":"https://www.wikidata.org/wiki/Q332796","display_name":"Survivorship curve","level":3,"score":0.7805558443069458},{"id":"https://openalex.org/C107130276","wikidata":"https://www.wikidata.org/wiki/Q133805","display_name":"Epidemiology","level":2,"score":0.6382523775100708},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.409185528755188},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.3875158131122589},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29733723402023315},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1607384979724884}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002294","descriptor_name":"Carcinoma, Squamous Cell","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D002294","descriptor_name":"Carcinoma, Squamous Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002294","descriptor_name":"Carcinoma, Squamous Cell","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D002294","descriptor_name":"Carcinoma, Squamous Cell","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D002985","descriptor_name":"Clinical Protocols","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.2217/fon-2019-0762","doi":"https://doi.org/10.2217/fon-2019-0762","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon-2019-0762","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},{"id":"pmid:31951149","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31951149","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future oncology (London, England)","raw_type":"Clinical Trial, Phase IV"},{"id":"pmh:oai:scholarlycommons.baptisthealth.net:se-all-publications-4615","doi":null,"is_oa":false,"landing_page_url":"https://scholarlycommons.baptisthealth.net/se-all-publications/3412","pdf_url":null,"source":{"id":"https://openalex.org/S4377196589","display_name":"Scholarly Commons - Baptist Health South Florida (Baptist Health South Florida)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210097785","host_organization_name":"Baptist Health South Florida","host_organization_lineage":["https://openalex.org/I4210097785"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"All Publications","raw_type":"text"}],"best_oa_location":{"id":"doi:10.2217/fon-2019-0762","doi":"https://doi.org/10.2217/fon-2019-0762","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon-2019-0762","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320311600","display_name":"Regeneron Pharmaceuticals","ror":"https://ror.org/02f51rf24"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W1529230314","https://openalex.org/W2040600853","https://openalex.org/W2084728935","https://openalex.org/W2155752258","https://openalex.org/W2163076565","https://openalex.org/W2380316500","https://openalex.org/W2593714049","https://openalex.org/W2759377993","https://openalex.org/W2794895085","https://openalex.org/W2797943369","https://openalex.org/W2805968856","https://openalex.org/W2898518424","https://openalex.org/W2913231688","https://openalex.org/W2941322994","https://openalex.org/W2947552510","https://openalex.org/W2947566748","https://openalex.org/W2947684310"],"related_works":["https://openalex.org/W4295817506","https://openalex.org/W4324057580","https://openalex.org/W7154968282","https://openalex.org/W4410816417","https://openalex.org/W3099397983","https://openalex.org/W3087858162","https://openalex.org/W7134807312","https://openalex.org/W4237433135","https://openalex.org/W7141476015","https://openalex.org/W4220804976"],"abstract_inverted_index":{"In":[0,36],"2018,":[1],"cemiplimab-rwlc":[2],"became":[3],"the":[4,10,46,50,58],"first":[5],"systemic":[6],"treatment":[7],"approved":[8],"by":[9,42],"US":[11],"FDA":[12],"for":[13,30,49],"patients":[14,66,92],"with":[15,67,93],"metastatic":[16],"cutaneous":[17],"squamous":[18],"cell":[19],"carcinoma":[20],"(CSCC)":[21],"or":[22,33,100],"locally":[23],"advanced":[24,68,94],"CSCC":[25,69,95],"who":[26,96,101],"are":[27],"not":[28],"candidates":[29],"curative":[31,34],"surgery":[32],"radiation.":[35],"2019,":[37],"conditional":[38],"approvals":[39],"were":[40],"granted":[41],"Health":[43],"Canada":[44],"and":[45,63,76,86],"European":[47],"Commission":[48],"same":[51],"indications.":[52],"Limited":[53],"data":[54],"exist":[55],"pertaining":[56],"to":[57,103],"clinical":[59,72],"characteristics,":[60],"disease":[61],"progression":[62],"survivorship":[64,85],"of":[65],"in":[70,106],"real-world":[71,108],"practice.":[73],"CemiplimAb-rwlc":[74],"Survivorship":[75],"Epidemiology":[77],"(CASE)":[78],"is":[79],"a":[80,107],"prospective":[81],"Phase":[82],"IV,":[83],"noninterventional,":[84],"epidemiology":[87],"study":[88],"that":[89],"will":[90],"enroll":[91],"have":[97],"recently":[98],"initiated":[99],"plan":[102],"receive":[104],"cemiplimab":[105],"setting.":[109],"Trial":[110],"registration":[111],"number:":[112],"NCT03836105.":[113]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":3}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2020-01-23T00:00:00"}